iRIS serves oncology trials at Beth Israel Deaconess Medical Center, Boston Children's Hospital, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, and other affiliated institutions. 

Visit the iRIS Wiki for more details.
ANNOUNCEMENT
Dear DF/HCC Research Community,
 
We will be holding a special iRIS Office Hours session on Tuesday, May 25th at 11am focused on Phase I clinical trials. If you work on Phase I or Phase I/II trials in iRIS, please try to attend. A recording will be posted for anyone who is unable to join the session live.

In this session, the topics will include:
 
·     NEW Changes to Phase I Order Set build process effective May 25, 2021.
·     When to use a Dose/Cohort Open/Close form vs. Amendment
·     Strategies for managing multiple amendment submissions
 
Please submit additional topics and questions in advance using the link below.
Note: Pre-registration is not required. Please use the attachment to save this session to your calendar.
Oncology trials in Boston are a collaborative effort involving many from many institutions. The transition to this new system, iRIS, represents an opportunity to streamline all of the processes involved, and move trials from submission to activation, and to our patients, more quickly. Please take advantage of all of the provided information and resources to help us make this transition as seamless as possible.

Sincerely,
Jeffrey Meyerhardt, MD, MPH
Associate Director for Clinical Trials,
Dana-Farber/Harvard Cancer Center
Drew Memmott
Associate Director for Administration,
Dana-Farber/Harvard Cancer Center
Erica Woulf
Senior Director for Research Informatics Operations,
Dana-Farber/Harvard Cancer Center